Union Korea Pharm Completes Capital Reduction and Rights Offering Under Rehabilitation Plan, Diluting Existing Shareholders by 75%
The capital reduction was completed on June 26, 2026, with 39,715,424 common shares cancelled, reducing outstanding shares to 19,854,006.
Subsequently, 60,000,000 new shares were issued via a third-party allotment, increasing total shares to 79,854,006 and capital to 39,927,003,000 KRW.
Existing shareholders experienced approximately 75% dilution due to the combination of stock consolidation and new issuance, severely impairing shareholder value.
This action is part of a court-approved rehabilitation plan aimed at normalizing operations, but it is expected to pressure the stock price in the near term.
[AI Summary]The completion of capital reduction and equity offering under the rehabilitation plan has massively diluted existing shareholders, and the use of proceeds and turnaround progress will be key stock price drivers.